ROS-Generating Poly(Ethylene Glycol)-Conjugated Fe3O4 Nanoparticles as Cancer-Targeting Sustained Release Carrier of Doxorubicin
Boddu Adilakshmi,Obireddy Sreekanth Reddy,Duddekunta Hemalatha,Kummari S V Krishna Rao,Wing-Fu Lai,Kummari SV Krishna Rao
DOI: https://doi.org/10.2147/IJN.S379200
IF: 7.033
2022-10-21
International Journal of Nanomedicine
Abstract:Boddu Adilakshmi, 1 Obireddy Sreekanth Reddy, 2– 4 Duddekunta Hemalatha, 1 Kummari SV Krishna Rao, 1 Wing-Fu Lai 2, 3 1 Polymer Biomaterial Design and Synthesis Laboratory, Department of Chemistry, Yogi Vemana University, Kadapa, Andhra Pradesh, 516005, India; 2 Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Zhejiang, 310012, People's Republic of China; 3 Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong Special Administrative Region, People's Republic of China; 4 Department of Chemistry, Sri Krishnadevaraya University, Anantapuramu, Andhra Pradesh, 515003, India Correspondence: Wing-Fu Lai; Kummari SV Krishna Rao, Email ; Purpose: Site-specific drug delivery systems can contribute to the development and execution of effective cancer treatment. Due to its favorable features (including high biocompatibility, high hydrophilicity and ease of functionalization), poly(ethylene glycol) (PEG) has been widely adopted to design drug carriers. Generating carriers for delivery of hydrophobic anticancer agents, however, is still a challenge in carrier design. Methods: In the first step, PEG is functionalized with dialdehyde to generate PEG-(CHO) 2 using EDC/NHS chemistry. In the second step, Fe 3 O 4 nanoparticles are functionalized with amino groups to generate Fe 3 O 4 -NH 2 . In the third step, PEG-(CHO) 2 , Fe 3 O 4 -NH 2 and doxorubicin (DOX) react in an acidic environment to yield a drug conjugate (PEGDA-MN-DOX), which is subsequently characterized by FT-IR, 1 H-NMR, SEM, TEM, DLS, TGA, and DSC. Results: The chemical functionalities of the drug conjugate are confirmed by FTIR, H-NMRand XRD analysis.The release pattern of PEGDA-MN-DOX is investigated at 25 and 37 °C at different pH values. The results indicate that the developed drug conjugate cannot only behave as a sustained-release carrier, but can also generate a significant level of reactive oxygen species (ROS), leading to a high level of toxicity against MCF-7 cells while still showing excellent biocompatibility in 3T3 cells. Conclusion: The reported conjugate shows anticancer potential, cancer-targeting ability, and ROS-generating capacity for effective drug encapsulation and sustained release in chemotherapy. Graphical Abstarct: Keywords: PEG, doxorubicin, magnetic nanoparticles, anti-cancer, biocompatibility, drug delivery Graphical Cancer is a group of diseases characterized by abnormal cell proliferation. According to a recent global projection, the number of cancer sufferers will exceed 15 million by 2020, 1 with 13.1 million people being killed by the disease by 2030. 2 Doxorubicin is an anthracycline drug that has been widely used in cancer treatment. Despite its broad-spectrum anticancer activity, its clinical use has been limited by its adverse effects, particularly cardiotoxicity. This is especially true for patients with advanced illnesses who need a high dose. This problem, however, has been ameliorated by recent advances in nanotechnology. A good example is the emergence of liposomal doxorubicin hydrochloride injection, which is the first clinically approved liposomal formulation to work against solid tumors, transplantable leukemias, and lymphomas. 3 Another example is magnetite nanoparticles (MNs) and other magnetic nanoparticles with high saturation magnetization and magnetic susceptibility. These nanoparticles have attracted research interest because the magnetic characteristics enable applications in medical diagnosis and treatment, ranging from immunoassay and magnetic resonance imaging to hyperthermia. 4–6 All these demonstrate the promising potential of nanomaterials in biomedical applications. 4–10 As far as drug delivery using nanocarriers is concerned, one of the most significant biological barriers to be tackled is opsonization. Opsonin is a protein found in blood serum. It can bind to conventional non-stealth nanoparticles, allowing mononuclear phagocytic system (MPS) macrophages to recognize and eliminate these nanoparticles before they can perform their intended therapeutic function. A few methods for masking or camouflaging nanoparticles have been developed. Poly(ethylene glycol) (PEG) conjugation to the surface of nanoparticles is one of these methods. The addition of PEG and PEG-containing copolymers to the nanoparticle surface significantly increases the blood circulation half-life of the nanoparticles. This technique creates a hydrophilic barrier around the nano -Abstract Truncated-